Previous 10 | Next 10 |
Lineage Reported 1Q22. Lineage Cell Therapies reported a loss of $7.1 million or $(0.04) per share. Revenues included recognition of a portion of the payment from the Roche/Genentech collaboration, with revenue to be recognized each quarter as obligations under the agreement are completed. Tot...
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Conference Call May 12, 2022, 4:30 PM ET Company Participants Brian Culley – Chief Executive Officer Gary Hogge – Senior Vice President of Clinical and Medical Affairs Ioana Hone – Director of Investor Relations Conf...
Lineage Cell Therapeutics press release (NYSE:LCTX): Q1 GAAP EPS of -$0.04 misses by $0.02. Revenue of $5.24M misses by $3.66M. Cash and Cash Equivalents of $78.1 Million as of March 31, 2022 For further details see: Lineage Cell Therapeutics GAAP EPS of -$0.04 misses by $0.02, revenue ...
Reported RG6501 (OpRegen ® ) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five Dry AMD Patients Expanded Pipeline with Two New Cell Therapy Development Programs; Auditory Neurons and Photoreceptors Announced Completi...
AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2022 financial and operating results on Thursday, May 12, 2022, ...
OpRegen Data Presented At ARVO. Lineage Cell Therapeutics presented data from the Phase 1/2a trial testing OpRegen, its retinal pigment epithelial cell transplantation for treating age-related macular degeneration (dry AMD). The data was presented at the Annual Meeting of the Association for R...
Phase 1/2a results for Lineage Cell Therapeutics' (NYSE:LCTX) RG6501 (OpRegen), a retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration, indicated the potential to slow, stop or reverse disease progression. In one cohort, patien...
12-Month Primary Endpoint Data Suggest OpRegen is Well Tolerated with an Acceptable Safety Profile Preliminary Evidence of Visual Function and Outer Retinal Structure Improvements Observed in Cohort 4 Patients with GA and Impaired Vision Data Reported at 2022 ARVO Me...
Lineage Cell Therapeutics (LCTX) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...